The Latest Cardiac and Vascular News
NEW YORK–(BUSINESS WIRE)–Synchron, a brain-computer interface company, today announced positive results from the COMMAND study evaluating the safety and efficacy of the Synchron brain computer interface (BCI) device in six participants over a 12-month period. “The COMMAND study results represent […]
NEW YORK–(BUSINESS WIRE)–Synchron, the endovascular brain-computer interface (BCI) company developing technology to restore functionality in patients with severe paralysis, today announced completion of patient enrollment in the US-based COMMAND trial. “We look forward to announcing the results from our COMMAND […]
Top-tier investor syndicate includes new investors ARCH Venture Partners, Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X, with follow on participation from existing investors including Khosla Ventures, NeuroTechnology Investors, METIS, Forepont […]
NEW YORK–(BUSINESS WIRE)–Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding […]
– Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. – Paralysis is a devastating condition for more than 5 million patients in the United States NEW YORK & MELBOURNE, Australia–(BUSINESS WIRE)–Synchron, an […]
Clinical trial to pave the way for Synchron’s StentrodeTM to become first commercially available implantable brain computer interface NEW YORK–(BUSINESS WIRE)–Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its […]
Synchron’s flagship StentrodeTM endovascular implant does not require open brain surgery and has obtained FDA Breakthrough Device Designation for the treatment of paralysis The New York based company is already conducting human trials in Australia and is expected to commence a […]
Synchron’s Stentrode is a fully-implantable brain-computer interface being designed to enable people with paralysis to restore functional independence by engaging in activities of daily living SAN FRANCISCO & NEW YORK CITY & MELBOURNE, Australia–(BUSINESS WIRE)–Synchron Inc., a neurovascular bioelectronic medicine […]
